摘要
目的探讨顺尔宁治疗儿童咳嗽变异性哮喘的临床价值。方法选取咳嗽变异性哮喘患儿120例,将患儿随机分为对照组及观察组各60例,对照组常规应用博利康尼、酮替芬治疗,疗程4周;观察组在对照组的基础上加用顺尔宁:2～5岁4mg,6～14岁5mg,均在每晚睡前顿服,疗程4周。结果两组患儿经治疗后均取得临床缓解,观察组咳嗽缓解时间及咳嗽消失时间均明显短于对照组;随访(9.72±2.17)个月,观察组复发率低于对照组(P<0.05);两组不良反应症状均轻微,坚持用药后症状消失,未影响治疗。结论顺尔宁治疗咳嗽变异性哮喘可快速控制哮喘急性发作,改善症状及体征,降低复发率,值得推广。
Objective To explore the clinical value of singulair for treating children cough variant asthma. Methods 120 cases of pediatric patients with cough variant asthma were selected and randomized into the control group and the observation group with 60 cases in each. The , ：rol group routinely received bricauyl and ketotifen with a course of four weeks and the observation group added with singulair based un the control group： 4rag for 2-5 years old and 5rag for 6-14 years old, all p.o every night before bedtime for 4 weeks. Results The pediatric patients of two groups all achieved clinical remission after treatment; Cough relief time and cough disappearance time of the observation group were significantly shorter than those of the control group; After follow-up of （ 9.72 ±2.17 ） months, the recurrence rate of observation group was lower than that of control group （ P 〈 0.05 ） ; Symptoms of adverse reactions in two groups were mild and disappeared after adhering to medication and did not affect the treatment. Conclusion The treatment of cough variant asthma with singulair can quickly control acute asthma attacks, improve symptoms and signs, reduce the relapse rate, and is worthy of clinical promotion.
出处
《中国现代医生》
2011年第17期155-156,共2页
China Modern Doctor
